肺部立体定向消融放疗后的动态影像学变化及假性进展的预测因素
该回顾性研究纳入104例患者共109个接受肺部立体定向消融放疗(SABR)且影像随访≥24个月无明确局部复发的病灶,分析系列CT演变规律。结果显示86%病灶出现肿块样实变,CT演变呈三阶段,68%病灶最大径较初始肿瘤增加>20%且50%发生在第三阶段,计划靶区体积(PTV)是假性进展的独立预测因素(校正OR 0.98,95%CI 0.97-0.99,P=0.002)。
要点
- SABR后86%(94/109)病灶出现肿块样实变,CT演变呈三阶段动态过程。
- 68%(74/109)病灶最大径较初始肿瘤增加>20%,其中50%发生于第三阶段。
- 计划靶区体积(PTV)是假性进展的独立预测因素(校正OR 0.98,95%CI 0.97-0.99,P=0.002)。
核心结论
- SABR后动态CT演变常表现为肿块样实变,假性进展发生率高;PTV独立预测该现象,提示随访中需谨慎解读影像学增大。
研究设计与样本
- 回顾性纳入接受SABR且影像随访≥24个月无明确局部复发的患者,共104例患者109个病灶,中位随访53个月;以初始(SABR前)肿瘤为参照测量演变病灶最大径。
关键影像表现/征象
- 肿块样实变见于94/109(86%)病灶。
- CT演变分三阶段:起始阶段为紧邻目标肿瘤的网状浸润影(中位3个月,范围1-9个月);发展阶段为密度增高伴斑片/条索状影和/或纤维化实变(中位4.5个月,范围1.5-15.5个月);肿块样实变阶段为组织化/吸收或收缩,最终形成肿块样实变(中位13个月,范围5.5-39个月)。
- 74/109(68%)病灶最大径较初始肿瘤增加>20%,其中50%发生于第三阶段。
诊断标准与关键数值
- 假性进展定义为随访中最大径较初始肿瘤增加>20%,随后影像学稳定,且无病理或临床复发证据。
临床应用与阅片要点
- SABR后随访中病灶增大>20%可能为假性进展,尤其发生于第三阶段(中位13个月)时。
- PTV是假性进展的独立预测因素(校正OR 0.98,95%CI 0.97-0.99,P=0.002),解读影像学增大时需结合该因素谨慎判断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Post-SABR radiologic appearances in the lung are dynamic and may imitate local failure. Although radiologic changes after SABR have been described, the dynamic evolution and predictors of pseudoprogression remain unclear. We aimed to characterize serial computed tomography (CT) evolution after SABR and examine its association with pseudoprogression.
MATERIALS AND METHODS: We retrospectively included patients who underwent SABR and had ≥24 months radiologic follow-up without definite local recurrence. The maximum diameter of the evolving post-SABR lesion was referenced to the initial (pre-SABR) tumor. Pseudoprogression was defined as any >20% increase in maximum diameter during follow-up that was followed by radiographic stabilization and lacked pathologic or clinical evidence of recurrence.
RESULTS: We evaluated 109 lesions from 104 patients (median follow-up, 53 months). Mass-like consolidation developed in 94/109 (86%) lesions. CT evolution followed three phases with typical onset: initiation-reticular infiltrates adjacent to the index tumor (median 3 months; range 1-9); development-increasing density with patchy/streaky opacities and/or fibrotic consolidation (median 4.5 months; range 1.5-15.5); and mass-like consolidation-organization/absorption or retraction culminating in a final mass-like consolidation (median 13 months; range 5.5-39). A total of 74 (68%) lesions showed a >20% increase vs the initial tumor, and 50% occurred during the third phase. Planning target volume (PTV) was an independent predictor of pseudoprogression (adjusted odds ratio 0.98, 95% CI 0.97-0.99; P = 0.002).
CONCLUSION: Dynamic CT evolution after SABR commonly manifests as mass-like consolidation with high rates of pseudoprogression. PTV independently predicts this phenomenon, underscoring the need for cautious interpretation of radiographic enlargement during follow-up.
引用
- Song X, Xu Q, Chen Y, et al. Dynamic Radiologic Changes and Predictors of Pseudoprogression After Lung Stereotactic Ablative Radiotherapy (SABR). Acad Radiol. 2026. PMID: 41775616. doi:10.1016/j.acra.2026.01.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。